TrialThe New England journal of medicine2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Georgina V Long et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
664 papers cite itlatest 60 shown
this paperpooled ittrialcites it